These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32631869)

  • 1. Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies.
    Ferreira WA; Chweih H; Lanaro C; Almeida CB; Brito PL; Gotardo EMF; Torres L; Miguel LI; Franco-Penteado CF; Leonardo FC; Garcia F; Saad STO; Frenette PS; Brockschnieder D; Costa FF; Stasch JP; Sandner P; Conran N
    J Pharmacol Exp Ther; 2020 Sep; 374(3):469-478. PubMed ID: 32631869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
    Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
    Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
    Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
    Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
    Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL
    Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant.
    Tawa M; Yamashita Y; Masuoka T; Nakano K; Yoshida J; Nishio M; Ishibashi T
    J Pharmacol Sci; 2019 May; 140(1):43-47. PubMed ID: 31036520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
    Bice JS; Keim Y; Stasch JP; Baxter GF
    Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
    Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
    Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
    Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE
    Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC.
    Elgert C; Rühle A; Sandner P; Behrends S
    Biochem Pharmacol; 2019 May; 163():142-153. PubMed ID: 30753814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.
    Baldissera L; Squebola-Cola DM; Calixto MC; Lima-Barbosa AP; Rennó AL; Anhê GF; Condino-Neto A; De Nucci G; Antunes E
    Pulm Pharmacol Ther; 2016 Dec; 41():86-95. PubMed ID: 27816773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats.
    Jabs A; Oelze M; Mikhed Y; Stamm P; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Kopp M; Steven S; Schulz E; Stasch JP; Münzel T; Daiber A
    Vascul Pharmacol; 2015 Aug; 71():181-91. PubMed ID: 25869522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging does not affect soluble guanylate cyclase redox state in mouse aortas.
    Shimosato T; Tawa M; Iwasaki H; Imamura T; Okamura T
    Physiol Rep; 2016 May; 4(10):. PubMed ID: 27233303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs.
    Sömmer A; Sandner P; Behrends S
    Biochem Pharmacol; 2018 Jan; 147():10-20. PubMed ID: 29155144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
    Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
    Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cGMP modulation therapeutics for sickle cell disease.
    Conran N; Torres L
    Exp Biol Med (Maywood); 2019 Feb; 244(2):132-146. PubMed ID: 30691292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
    Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
    Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.